Zolpidem: An update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomia

Drugs

Volumn 59, Issue 4, 2000, Pages 865-889

  Holm, Kristin J ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CIMETIDINE; DESIPRAMINE; DOXYLAMINE; FLUNITRAZEPAM; FLUOXETINE; FLURAZEPAM; IMIPRAMINE; ITRACONAZOLE; KETOCONAZOLE; NITRAZEPAM; RIFAMPICIN; RITONAVIR; TEMAZEPAM; TRAZODONE; TRIAZOLAM; VENLAFAXINE; WARFARIN; ZALEPLON; ZOLPIDEM; ZOPICLONE;

CLINICAL TRIAL; COGNITION; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG TOLERABILITY; DRUG USE; EXPERIMENTAL MODEL; HUMAN; HYPNOSIS; INSOMNIA; MEMORY; NAUSEA; NONHUMAN; PSYCHOMOTOR ACTIVITY; REVIEW; SEDATION; VERTIGO;

EID: 0034011740     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059040-00014     Document Type: Review

References (191)

1. 1. Langtry HD, Benfield P. Zolpidem: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990 Aug; 40: 291-313
2. 2. Abadic P, Rioux P, Scatton B, et al. Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography. Eur J Pharmacol 1996 Jan 4; 295: 35-44
3. 3. Sanger DJ, Depoortere H. The pharmacology and mechanism of action of zolpidem. CNS Drug Rev 1998; 4 (4): 323-40
4. 4. Biggio G, Concas A, Corda MG, et al. Enhancement of GABA-ergic transmission by zolpidem, an imidazopyridine with preferential affinity for type 1 benzodiazepine receptors. Eur J Pharmacol 1989; 161: 173-80
5. 5. Perrault G, Morel E, Sanger DJ, et al. Differences in pharmacological profiles of a new generation of benzodiazepine and non-benzodiazepine hypnotics. Eur J Pharmacol 1990 Oct 23; 187: 487-94
6. 6. Depoortere H, Zivkovic B, Lloyd KG, et al. Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther 1986; 237 (2): 649-58
7. 7. Walsh JK, Schweitzer PK, Sugerman JL, et al. Transient insomnia associated with a 3-hour phase advance of sleep time and treatment with zolpidem. J Clin Psychopharmacol 1990 Jun; 10: 184-9
8. 8. Roth T, Roehrs T, Vogel G. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Sleep 1995 May; 18: 246-51
9. 9. Mendelson WB. Effects of flurazepam and zolpidem on the perception of sleep in normal volunteers. Sleep 1995 Feb; 18: 88-91
10. 10. Gengo FM, Cwudzinski DM, Manning E. Residual daytime effects of zolpidem, lemazepam, and doxylamine in healthy volunteers [abstract]. 9th Annual Meeting of the Sleep Research Society; 1995 May 30; Nashville, Tennessee
11. 11. Erman M, Erwin C, Gengo F, et al. Efficacy of zolpidem and temazepam in transient insomnia [abstract]. 9th Annual Meeting of the Sleep Research Society; 1995 May 30; Nashville, Tennessee
12. 12. Uchiumi M, Sugiyama T, Suzuki M, et al. Effects of a single dose of zolpidem, triazolam and nitrazepam on daytime sleepiness. Jpn J Neuropsychopharmacol 1994; 16: 45-56
13. 13. Cluydts R, De Roeck J, Cosyns P, et al. Antagonizing the effects of experimentally induced sleep disturbance in healthy volunteers by lormetazepam and zolpidem. J Clin Psychopharmacol 1995 Apr; 15: 132-7
14. 14. Scharf MB, Mayleben DW, Kaffeman M, et al. Dose response effects of zolpidem in normal geriatric subjects. J Clin Psychiatry 1991 Feb; 52: 77-83
15. 15. Beaumont M, Goldenberg F, Lejeune D, et al. Effect of zolpidem on sleep and ventilatory patterns at simulated altitude of 4,000 meters. Am J Respir Crit Care Med 1996 Jun; 153 (Pt 1): 1864-9
16. 16. Quera-Salva MA, McCann C, Boudet J, et al. Effects of zolpidem on sleep architecture, night time ventilation, daytime vigilance and performance in heavy snorers. Br J Clin Pharmacol 1994 Jun; 37: 539-43
17. 17. Morgan PJ, Chapados R, Chung FF, et al. Evaluation of zolpidem, triazolam, and placebo as hypnotic drugs the night before surgery. J Clin Anesth 1997 Mar; 9: 97-102
18. 18. Jamieson A, Zammit G, Walsh J, et al. Zolpidem improves sleep in travelers following eastward transatlantic flight [abstract]. Eur Neuropsychopharmacol 1998 Nov; 8 Suppl. 2: S294-295
19. 19. Blois R, Gaillard J-M, Attali P, et al. Effect of zolpidem on sleep in healthy subjects: a placebo-controlled trial with polysomnographic recordings. Clin Ther 1993 Sep-Oct; 15: 797-809
20. 20. Patat A, Trocherie S, Thebault JJ, et al. EEG profile of intravenous zolpidem in healthy volunteers. Psychopharmacology 1994 Feb; 114: 138-46
21. 21. Benoit O, Bouard G, Payan C, et al. Effect of a single dose (10 mg) of zolpidem on visual and spectral analysis of sleep in young poor sleepers. Psychopharmacology 1994 Nov; 116: 297-303
22. 22. Brunner DP, Dijk D-J, Munch M, et al. Effect of zolpidem on sleep and sleep EEG spectra in healthy young men. Psychopharmacology 1991; 104 (1): 1-5
23. 23. Gieschke R, Cluydts R, Dingemanse J, et al. Effects of bretazenil vs. zolpidem and placebo on experimentally induced sleep disturbance in healthy volunteers. Methods Find Exp Clin Pharmacol 1994 Nov; 16: 667-75
24. 24. Guieu JD, Derambure P, Dujardin K, et al. Effects of a simple dose of zolpidem, zopiclone, flunitrazepam and placebo on sleep EEG microstructure [abstract]. J Sleep Res 1996; 5 Suppl. 1: 81
25. 25. Kanno O, Watanabe H, Nakagome K. Effects of zolpidem and triazolam on sleep and daytime activities in normal young volunteers. Jpn J Neuropsychopharmacol 1993; 15: 589-602
26. 26. Steens RD, Pouliot Z, Millar TW, et al. Effects of zolpidem and triazolam on sleep and respiration in mild to moderate chronic obstructive pulmonary disease. Sleep 1993 Jun; 16: 318-26
27. 27. Vermeeren A, O'Hanlon JF, Declerck AC, et al. Acute effects of zolpidem and flunitrazepam on sleep, memory and driving performance, compared to those of partial sleep deprivation and placebo. Acta Ther 1995; 21 (1): 47-64
28. 28. Hermann WM. Kubicki ST, Boden S, et al. Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic 'learned' insomnia: psychometric and polysomnographic evaluation. J Int Med Res 1993 Nov-Dec; 21: 306-22
29. 29. Scharf MB, Roth T, Vogel GW, et al. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994 May; 55: 192-9
30. 30. Monti JM, Attali P, Monti D, et al. Zolpidem and rebound insomnia - a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry 1994 Jul; 27: 166-75
31. 31. Terzano MG, Parrino L, Boselli M, et al. Sensitivity of cyclic alternating pattern to prolonged pharmacotherapy: a 5-week study evaluating zolpidem in insomniac patients. Clin Neuropharmacol 1997 Oct; 20: 447-54
32. 32. Parrino L, Smerieri A. Spaggiari MC, et al. Modifications of sleep structure in insomniac patients treated with zolpidem and zopiclone [abstract]. Sleep Res 1999; 2 Suppl. 1
33. 33. Scharf M, Vogel G, Kaffeman M, et al. Dose-response of zolpidem in elderly patients with chronic insomnia [abstract]. Sleep Res 1991; 20: 84
34. 34. Parrino L, Terzano MG. Polysomnographic effects of hypnotic drugs: a review. Psychopharmacology 1996 Jul; 126: 1-16
35. 35. Ferrillo F, Balestra V, De-Carli F, et al. Effects of the administration of zolpidem and triazolam on the dynamics of EEG slow waves during sleep [abstract]. J Sleep Res 1992; 1 Suppl. 1: 72
36. 36. Dujardin K, Guieu JD, Leconte-Lambert C, et al. Comparison of the effects of zolpidem and flunitrazepam on sleep structure and daytime cognitive functions: a study of untreated insomniacs. Pharmacopsychiatry 1998 Jan; 31: 14-8
37. 37. Nakajima T, Sasaki T, Kanno O, et al. Effects of zolpidem and zopiclone on night sleep and daytime activity in healthy volunteers: a polysomnographic study [abstract]. XXIst Collegium Internationale Neuro-psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, Scotland
38. 38. Parrino L, Boselli M, Spaggiari MC, et al. Multidrug comparison (lorazepam, triazolam, zolpidem, and zopiclone) in situational insomnia: polysomnographic analysis by means of cyclic alternating pattern. Clin Neuropharmacol 1997 Jun; 20: 253-63
39. 39. Fleming J, Moldofsky H, Walsh JK, et al. Comparison of the residual effects and efficacy of short term zolpidem, flurazepam and placebo in patients with chronic insomnia. Clin Drug Invest 1995 Jun; 9: 303-13
40. 40. Allain H, Patat A, Lieury A, et al. Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics. Eur Psychiatry 1995; 10 Suppl. 3: 129s-35s
41. 41. Wesensten NJ, Balkin TJ, Belenky GL. Effects of daytime administration of zolpidem versus triazolam on memory. Eur J Clin Pharmacol 1995; 48 (2): 115-22
42. 42. Berlin I, Warot D, Hergueta T, et al. Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J Clin Psychopharmacol 1993 Apr; 13: 100-6
43. 43. Troy S, Darwish M. Maximal and residual effects: zaleplon vs zolpidem and triazolam [poster]. 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg
44. 44. Sicard BA, Trocherie S, Morcau J, et al. Evaluation of zolpidem on alertness and psychomotor abilities among aviation ground personnel and pilots. Aviat Space Environ Med 1993 May; 64: 371-5
45. 45. Greenblatt DJ, Harmatz JS, Wright CE, et al. Does zolpidem have unique clinical properties? A pharmacodynamic comparison with triazolam and placebo [abstract]. Clin Pharmacol Ther 1996 Feb; 59: 178
46. 46. Mintzer MZ, Frey JM, Yingling JE, et al. Triazolam and zolpidem: a comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers. Behav Pharmacol 1997 Nov; 8 Spec, issue: 561-74
47. 47. Rush CR, Griffiths RR. Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers. J Clin Psychopharmacol 1996 Apr; 16: 146-57
48. 48. Wesensten NJ, Balkin TJ, Belenky GL. Effects of daytime administration of zolpidem and triazolam on performance. Aviat Space Environ Med 1996 Feb; 67: 115-20
49. 49. Greenblatt DJ, Harmatz JS, von MLL, et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther 1998 Nov; 64: 553-61
50. 50. Troy S, Darwish M. Zaleplon: minimal functional impairment vs other hypnotics [abstract], 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg
51. 51. Danjou P, Paly I, Fruncillo R, et al. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. Br J Pharmacol 1999; 48: 367-74
52. 52. Bocca ML, Le-Doze F, Etard O, et al. Residual effects of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades. Psychopharmacology 1999; 143: 373-9
53. 53. Hergueta T, Molinier P, Olivieri Apicella N, et al. Effects of loprazolam, zolpidem and zopiclone on memory, vigilance and postural control during nocturnal and morning awakenings in healthy subjects [abstract]. Methods Find Exp Clin Pharmacol 1996; 18 Suppl. B: 203
54. 54. Uchiumi M, Suzuki M, Isawa S, et al. Effects of zolpidem and zopiclone on daytime sleepiness [abstract]. Collegium Internationale Neuro-Psychopharmacologicum Regional Meeting: 1997 Aug 21-23; Acapulco, Mexico
55. 55. Uchiumi M, Isawa S, Suzuki M, et al. The effects of zolpidem and zopiclone on daytime sleepiness and psychomotor performance. Fujisawa-Synthelabo (Japan). 1996 (Data on file)
56. 56. The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products European Public Assessment Report: Sonata. Report no.: CPMP/897/99.
57. 57. Wyeth-Ayerst. Zaleplon prescribing information. US, 1999
58. 58. Fairweather DB, Kerr JS, Hindmarch I. The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur J Pharmacol 1992 Dec; 43: 597-601
59. 59. Wilkinson CJ. The acute effects of zolpidem, administered alone and with alcohol, on cognitive and psychomotor function. J Clin Psychiatry 1995 Jul; 56: 309-18
60. 60. Jackson JL, Louwerens JW, Cnossen F, et al. Testing the effects of the imidazopyridine zolpidem on memory: an ecologically valid approach. Hum Psychopharm 1992 Sep-Oct; 7: 325-30
61. 61. Mintzer MZ, Griffiths RR. Selective effects of zolpidem on human memory functions. J Psychopharmacol 1999 Mar; 13: 18-31
62. 62. Balkin TJ, Wesensten NJ, Belenky GL. Triazolam versus zolpidem I: effects on memory [abstract]. Sleep Res 1994; 23: 62
63. 63. Weerts EM, Ator NA, Grech DM, et al. Zolpidem physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. J Pharmacol Exp Ther 1998 Apr; 285: 41-53
64. 64. Weerts EM, Griffiths RR. Zolpidem self-injection with concurrent physical dependence under conditions of long-term continuous availability in baboons. Behav Pharmacol 1998 May; 9: 285-97
65. 65. Griffiths RR, Sannerud CA, Ator NA, et al. Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal. J Pharmacol Exp Ther 1992 Mar; 260: 1199-208
66. 66. Rush CR. Behavioral pharmacology of zolpidem relative to benzodiazepines: a review. Pharmacol Biochem Behav 1998 Nov; 61: 253-69
67. 67. Stephens DN, Sanger DJ. The abuse and dependence liabilities of zolpidem. In: Freeman H, Puech AJ, Roth T, editors. Zolpidem: an update of its pharmacological properties. Paris: Elsevier, 1996: 73-86
68. 68. Rush CR, Madakasira S, Goldman NH, et al. Discriminative stimulus effects of zolpidem in pentobarbital-trained subjects: II. Comparison with triazolam and caffeine in humans. J Pharmacol Exp Ther 1997 Jan; 280: 174-88
69. 69. Mintzer MZ, Frey JM, Griffiths RR. Zolpidem is differentiated from triazolam in humans using a three-response drug discrimination procedure. Behav Pharmacol 1998 Nov; 9: 545-59
70. 70. Rush CR, Baker RW, Wright K. Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans. Psychopharmacology 1999; 144: 220-33
71. 71. Evans SM, Funderburk FR. Griffiths R. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther 1990 Dec; 255: 1246-55
72. 72. Wilkinson CJ. The abuse potential of zolpidem administered alone and with alcohol. Pharmacol Biochem Behav 1998 May; 60: 193-202
73. 73. Serra M, Concas A, Biggio G. Failure of long-term administration of zopiclone and zolpidem to induce tolerance in mice. Neurosci Res Commun 1996 Nov-Dec; 19: 169-78
74. 74. Perrault G, Morel E, Sanger DJ, et al. Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem. J Pharmacol Exp Ther 1992 Oct; 263: 298-303
75. 75. Elliot EE, White JM. High doses of zolpidem do not produce withdrawal in rats [abstract]. Annual Scientific Meeting of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists; 1997 Nov 30 - Dec 3; Canberra, Australia
76. 76. Cohen C, Sanger DJ. Effects of chronic treatment with triazolam on operant responding in rats. Pharmacol Biochem Behav 1994 Nov; 49: 455-61
77. 77. Cohn MA. Effects of zolpidem, codeine phosphate and placebo on respiration: a double-blind, crossover study in volunteers. Drug Saf 1993 Oct; 9: 312-9
78. 78. McCann CC. Quera-Salva MA, Boudet J, et al. Effect of zolpidem during sleep on ventilation and cardiovascular variables in normal subjects. Fundam Clin Pharmacol 1993; 7 (6): 305-10
79. 79. Murciano D, Armengaud MH, Cramer PH, et al. Acute effects of zolpidem, triazolam and flunitrazepam on arterial blood gases and control of breathing in severe COPD. Eur Respir J 1993 May; 6: 625-9
80. 80. Girault C, Muir J-F, Mihaltan F, et al. Effects of repeated administration of zolpidem on sleep, diurnal and nocturnal respiratory function, vigilance, and physical performance in patients with COPD. Chest 1996 Nov; 110: 1203-11
81. 81. Murciano D, Moreau J, Barthouil P, et al. Long term effects of zolpidem (z) on arterial blood gases and control of breathing in patients with severe chronic obstructive pulmonary disease (COPD) [abstract]. Am Rev Respir Dis 1992 Apr; 145: A636
82. 82. Cirignotta F, Mondini S, Zucconi M, et al. Controlled polysomnographic study of the effects of benzodiazepine and nonbenzodiazepine hypnotics (zolpidem) in obstructive sleep apnea patients: preliminary results. In: Sauvanet JP et al., editors. Imidazopyridines in sleep disorders. New York: Raven Press, 1988: 297-304
83. 83. Rosenzweig P, Colle M, Bianchetti G, et al. Nocturnal hormonal profiles after zolpidem in healthy male volunteers [abstract]. Clin Pharmacol Ther 1998 Feb; 63: 187
84. 84. Colle M, Rosenzweig P, Bianchetti G, et al. Nocturnal profile of growth hormone secretion during sleep induced by zolpidem: a double-blind study in young adults and children. Horm Res 1991 Jan; 35: 30-4
85. 85. Copinschi G, Akseki E, Moreno-Reyes R, et al. Effects of bedtime administration of zolpidem on circadian and sleep-related hormonal profiles in normal women. Sleep 1995 Jul; 18: 417-24
86. 86. Fraisse J, Garrigou-Gadenne D, Thém JP. Pharmacokinetic and metabolic profiles of zolpidem. In: Freeman H, Puech AJ, Roth T, editors. Zolpidem: an update of its pharmacological properties. Paris: Elsevier, 1996: 45-57
87. 87. von Moltke LL, Greenblatt DJ, Granda BW, et al. Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol 1999 Jul; 48: 89-97
88. 88. Fillastre JP, Geffroy-Josse S, Etienne I, et al. Pharmacokinetics and pharmacodynamics of zolpidem following repeated doses in hemodialyzed uraemic patients. Fundam Clin Pharmacol 1993; 7 (1): 1-9
89. 89. Hunt TL. Dose proportionality of oral zolpidem in normal healthy subjects. Sanofi-Synthelabo (Paris). LSH25; 1989 (Data on file)
90. 90. Ahrens J. Treatment of sleep disorders with zolpidem. Efficacy without potential dependency [in German]. Ther Schweiz 1993 Oct; 9: 660-2
91. 91. Cluydts RJ, De Roeck JM, Jolie AM. A three week multicentre general practitioner study of zolpidem in 651 patients with insomnia. Acta Ther 1993; 19 (1): 73-91
92. 92. Licciardello L, Licini P. Safety and efficacy of zolpidem therapy in sleep disorders: a multicenter trial in hospitalized patients. Curr Ther Res 1992 Nov; 52: 652-8
93. 93. Leger D, Roger M, Gerard D. Sleep/wake rhythm of a population of elderly insomniacs: study in 769 psychophysiological insomniacs receiving zolpidem [in French]. Rev Geriat 1998 Jan; 23: 73-84
94. 94. Dockhorn RJ, Dockhorn DW. Zolpidem in the treatment of short-term insomnia: a randomized, double-blind, placebo-controlled clinical trial. Clin Neuropharmacol 1996 Aug; 19: 333-40
95. 95. Fattapposta F, Sanarelli L, Valle E, et al. A double-blind study of the effects of zolpidem, a new imidazopyridine hypnotic, on contingent negative variation in patients with situational insomnia. Curr Ther Res 1990 Nov; 48: 766-73
96. 96. Lahmeyer H, Wilcox CS, Kann J, et al. Subjective efficacy of zolpidem in outpatients with chronic insomnia: a double-blind comparison with placebo. Clin Drug Invest 1997 Mar; 13: 134-44
97. 97. Monti JM, Monti D, Estévez F, et al. Sleep in patients with chronic primary insomnia during long-term zolpidem administration and after its withdrawal. Int Clin Psychopharmacol 1996 Dec; 11: 255-63
98. 98. Asnis GM, Chakraburtty A, DuBoff EA, et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 1999; 60 (10): 668-76
99. 99. Kazamatsuri H, Yamashita I, Sato M, et al. Clinical evaluation of zolpidem on insomnia of patients with schizophrenia and manic-depressive psychosis: double-blind trial in comparison with nitrazepam [in Japanese]. Rinsho Iyaku 1993; 9 (1): 107-36
100. 100. Kudo Y, Kawakita Y, Saito M, et al. Clinical efficacy and safety of zolpidem on insomnia - a double-blind comparative study with zolpidem and nitrazepam [in Japanese]. Rinsho Iyaku 1993; 9 (1): 79-105
101. 101. Rosenberg J, Ahlstrøm F. Randomized, double blind trial of zolpidem 10 mg versus triazolam 0.25 mg for treatment of insomnia in general practice. Scand J Prim Health Care 1994 Jun; 12: 88-92
102. 102. Silvestri R, Ferrillo F, Murri L, et al. Rebound insomnia after abrupt discontinuation of hypnotic treatment: double-blind randomized comparison of zolpidem versus triazolam. Hum Psychopharm 1996 May-Jun; 11: 225-33
103. 103. Tsutsui S, Katsura T, Kawano T, et al. Clinical study on zolpidem, sleep-inducing agent, in the fields of internal medicine and psychosomatic medicine. Double blind comparative study with triazolam as reference drug [in Japanese]. Rinsho Iyaku 1993; 9 (2): 387-413
104. 104. Kerkhof GA, van Vianen BG, Kamphuisen HAC, et al. A comparison of zolpidem and temazepam in psychophysiological insomniacs [abstract]. Eur Neuropsychopharmacol 1996 Sep; 6 Suppl. 4: 155-6
105. 105. Elie R, Rüther E, Farr I, et al. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J Clin Psychiatry 1999 Aug; 60 (8): 536-44
106. 106. Fry J, Scharf MB, Berkowitz DV, et al. A phase III, 28 day, multicenter, randomized, double-blind comparator- and placebo-controlled, parallel-group safely, tolerability, and efficacy study of 5, 10, and 20 mg. of zaleplon, compared with 10 mg. of zolpidem or placebo, in adult outpatients with insomnia [abstract]. Sleep 1998; 21 Suppl.: 262
107. 107. Schadeck B, Chelly M, Amsellem D, et al. Comparative efficacy of doxylamine (15 mg) and zolpidem (10 mg) for the treatment of common insomnia. A placebo-controlled study [in French]. Sem Hop 1996 Apr 18-25; 72: 428-39
108. 108. Tsutsui S, Okuse S, Hongo M, et al. Clinical investigation of zolpidem, a short-acting hypnotic, for the treatment of chronic insomnia in the departments of internal medicine and psychotherapy/internal medicine. Fujisawa-Synthelabo (Japan). 1999 (Data on file)
109. 109. Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Hum Psychopharm 1998 Apr: 13: 191-8
110. 110. Emeriau JP, Descamps A, Dechelotte P, et al. Zolpidem and flunitrazepam: a multicenter trial in elderly hospitalized patients. In: Sauvanet JP et al., editors. Imidazopyridines in sleep disorders. New York: Raven Press, 1988: 317-26
111. 111. Leppik IE, Roth-Schechter GB, Gray GW, et al. Double-blind, placebo-controlled comparison of zolpidem, triazolam, and temazepam in elderly patients with insomnia. Drug Dev Res 1997 Mar; 40: 230-8
112. 112. Roger M, Attali P, Coquelin J-P. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia. Clin Ther 1993 Jan-Feb; 15: 127-36
113. 113. Shaw SH, Curson H, Coquelin JP. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J Int Med Res 1992 Apr; 20: 150-61
114. 114. Pagot R, Cramer P, L'Heritier C, et al. Comparison of the efficacy and tolerability of zolpidem 20 mg and triazolam 0.5 mg in anxious or depressed insomniac patients. Curr Ther Res 1993 Jan; 53: 88-97
115. 115. Schlich D, L'Heritier C, Coquelin JP, et al. Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J Int Med Res 1991 May-Jun; 19: 271-9
116. 116. Scharf MB, Mendels J, Thorpy M, et al. Safety of long-term zolpidem treatment in patients with insomnia. Curr Ther Res 1994 Sep; 55: 1100-11
117. 117. Maarek L, Cramer P, Attali P. The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J Int Med Res 1992 Apr; 20: 162-70
118. 118. Kummer J, Guendel L, Linden J, et al. Long-term polysomnographic study of the efficacy and safety of zolpidem in elderly psychiatric in-patients with insomnia. J Int Med Res 1993 Jul-Aug; 21: 171-84
119. 119. Yamada M, Mizuki Y, Mashimoto S, et al. A long-term treatment of zolpidem, a new hypnotic, in a multicenter trial [in Japanese]. Rinsho Iyaku 1993; 9 Suppl. 2: 179-202
120. 120. Buzo Sanchez LG, Sanchez JM, Lopez Moreno JL. Dependence and tolerance with zolpidem. Am J Health System Pharm 1996 Nov 1; 53: 2638
121. 121. Cavallaro R, Grazia RM, Covelli G. Tolerance and withdrawal with zolpidem [letter]. Lancet 1993 Aug 7; 342: 374-5
122. 122. Gericke CA, Ludolph AC. Chronic abuse of zolpidem [letter]. JAMA 1994 Dec 14; 272: 1721-2
123. 123. Ravishankar A, Carnwath T. Zolpidem tolerance and dependence-two case reports. J Psychopharmacol 1998; 12: 103-4
124. 124. Bottlender R, Schütz C, Möller H-J, et al. Zolpidem dependence in a patient with former polysubstance abuse. Pharmacopsychiatry 1997 May; 30: 108
125. 125. Arbus L, Lavoisy J, Soubrane C, et al. Efficacy and safety of zolpidem 10 mg administered pro re nata (P.R.N) in patients with chronic insomnia: a multicenter, placebo-controlled study. Sleep Res Online 1999; 2 Suppl. 1: 129
126. 126. Walsh JK, Erman MK, Roth T, et al. Zolpidem 10 mg vs placebo for intermittent treatment of patients with primary insomnia. Synthelabo. LSH58; Oct 5, 1999 (Data on file)
127. 127. Cluydts R, Peeters K, De Bouyalsky I, et al. Comparison of continuous versus intermittent administration of zolpidem in chronic insomniacs: a double-blind, randomized pilot study. J Int Med Res 1998 Jan-Feb; 26: 13-24
128. 128. Allain H, Monti J. General safety profile of zolpidem: safety in elderly, overdose and rebound effects. Eur Psychiatry 1997; 12 Suppl. 1: 21s-9s
129. 129. Hajak G, Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16 944 cases. Int Clin Psychopharmacol 1998 Jul; 13: 157-67
130. 130. Bautista AHP, Buenaventura RD. Zolpidem in insomnia 3-year post-marketing surveillance study in the Phillipines. Phillipine J Psych 1998; XXII (2): 12-7
131. 131. Chaumet-Riffaud AE, Desforges C, Lavoisy J. Review of the post-marketing surveillance experience collected with zolpidem during the first three years after launch in Europe [abstract]. J Sleep Res 1992; 1 Suppl. 1: 40
132. 132. Lorex Synthélabo. Stilnoct(TM). In: ABP1 Compendium of Data Sheets and Summaries of Product Characteristics. London: Datapharm Publications Limited, 1998-99: 676-7
133. 133. Zolpidem tartrate.. In: McEvoy GK, editor. AHFS Drug Information(RM). Bethesda (MD): American Society of Health-System Pharmacists Inc., 1999: 2113-6
134. 134. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 1998 Jun; 32: 680-91
135. 135. Canaday BR. Amnesia possibly associated with zolpidem administration. Pharmacotherapy 1996 Jul-Aug; 16: 687-9
136. 136. van-Puijenbroek EP, Egberts ACG, Krom HJ. Visual hallucinations and amnesia associated with the use of zolpidem [letter]. Int J Clin Pharmacol Ther 1996 Jul; 34: 318
137. 137. Markowitz JS, Rames LJ, Reeves N, et al. Zolpidem and hallucinations. Ann Emerg Med 1997 Feb; 29: 300-1
138. 138. Pies RW. Dose-related sensory distortions with zolpidem. J Clin Psychiatry 1995 Jan; 56: 35-6
139. 139. Ansseau M, Pitchot W, Hansenne M, et al. Psychotic reactions to zolpidem. Lancet 1992 Mar 28; 339: 809
140. 140. Iruela LM, Ibañez.-Rojo V. Baca E. Zolpidem-induced macropsia in anorexic woman [letter]. Lancet 1993 Aug 14; 342: 443-4
141. 141. Markowitz JS, Brewerton TD. Zolpidem-induced psychosis. Ann Clin Psychiatry 1996 Jun; 8: 89-91
142. 142. Karsenti D, Blanc P, Bacq Y, et al. Hepatotoxicity associated with zolpidem treatment. BMJ 1999 May 1; 318: 1179
143. 143. Queneau PE, Koch S, Hrusovsky S. Cytolytic hepatitis related to zolpidem. 1st Int Symp Hepatol Clin Pharmacol 1994: 39
144. 144. Chevillard V, Veytrac G, Attali F, et al. Absence of zolpidem liver toxicity. Results of a French national pharmacovigilance survey [abstract]. 5th Annual Meeting of the European Society of Pharmacovigilance; 1997 Sep 15-16; Berlin
145. 145. Guerault E, Chaumet-Riffaud AE, Morselli PL, et al. Neurological adverse event profile in the elderly with zolpidem 5 and 10 mg: a retrospective evaluation of European phase II and III studies [abstract]. J Sleep Res 1992; 1 Suppl. 1: 89
146. 146. Unden M. Schechter BR. Next day effects after nighttime treatment with zolpidem: a review. Eur Psychiatry 1996; II Suppl. 1: 21s-30
147. 147. Ware CJ, Walsh JK, Scharf MB, et al. Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin Neuropharmacol 1997 Apr; 20: 116-25
148. 148. Voderholzer U, Riemann D, Hornyak M, et al. Polysomnographic withdrawal effects after zopiclone, zolpidem, triazolam and placebo treatment in healthy subjects [abstract]. Biol Psychiatry 1997 Jul 1; 42 Suppl.: 69S
149. 149. Guazzelli M, Ciapparelli A, Balsamo EL, et al. Treatment of insomnia related to depressive disorders. Effects of zolpidem versus flunitrazepam administration and withdrawal evaluated in a double-blind study [in Italian]. Minerva Psichiatr 1993 Sep; 34: 193-203
150. 150. Soldatos CR, Dikeos DG, Whitehead A. Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol 1999; 14 (5): 287-303
151. 151. Bruun TG. Abuse potential during use and withdrawal psychosis after treatment with the hypnotic zolpidem [in Danish]. Ugeskr Laeger 1993 Aug 30; 155: 2711-3
152. 152. Walsky E. Management of zolpidem withdrawal. J Clin Psychopharmacol 1996 Dec; 16: 459
153. 153. Gilbert DL, Staats PS. Seizure after withdrawal from supratherapeutic doses of zolpidem tartrate, a selective omega 1 benzodiazepine receptor agonist. J Pain Symptom Manage 1997 Aug; 14: 118-20
154. 154. Department of Health and Human Services Subtance Abuse and Mental Health Services Administration. Drug Abuse Warning Network Annual Medical Examiner Data 1997. :, 1997
155. 155. Tyrer P, Murphy S, Riley P. The Benzodiazepine Withdrawal Symptom Questionnaire. J Affect Disord 1990; 19 (1): 53-61
156. 156. Lemoine P, Allain H, Janus C, et al. Gradual withdrawal of zopiclone (7.5 mg) and zolpidem (10 mg) in insomniacs treated for at least 3 months. Eur Psychiatry 1995; 10 Suppl. 3: 161s-5s
157. 157. Garnier R, Guerault E, Muzard D, et al. Acute zolpidem poisoning - analysis of 344 cases. J Toxicol Clin Toxicol 1994; 32 (4): 391-404
158. 158. Renaud D, Royer-Morot MJ, Weber M, et al. Etude toxicoinetique des intoxications aigues par le zolpidem: 10 observations. XXVIIIème Congrès Français des Centres Anti-poisons; 3-5 Oct 1990
159. 159. Lichtenwalner M, Tully R. A fatality involving zolpidem. J Anal Toxicol 1997 Nov-Dec; 21: 567-9
160. 160. Meeker JE, Som CW, Macapagal EC, et al. Zolpidem tissue concentrations in a multiple drug related death involving Ambien. J Anal Toxicol 1995 Oct; 19: 531-4
161. 161. Winek CL, Wahba WW, Janssen JK, et al. Acute overdose of zolpidem: a case report. Forensic Sci Int 1996 Apr 23; 78: 165-8
162. 162. Tracqui A, Kintz P, Mangin P. A fatality involving two unusual compounds - zolpidem and acepromazine. Am J Forensic Med Pathol 1993 Dec; 14: 309-12
163. 2 antagonists, cimetidine and ranitidine. Int J Clin Pharmacol Res 1988; VIII (6): 471-6
164. 164. Harvengt C, Hulhoven R, Desager JP, et al. Drug interactions investigated with zolpidem. In: Sauvanet JP et al., editors. Imidazopyridines in sleep disorders. New York: Raven Press, 1988: 165-73
165. 165. Albin H, Vinçon G, Vinçon J, et al. Study of the pharmacokinetics of zolpidem in healthy volunteers after repeated administration: effect on antipyrine clearance. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders. New York: Raven Press, 1988: 369-70
166. 166. Desager JP, Hulhoven R, Harvengt C, et al. Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic. Psychopharmacology 1988; 96: 63-6
167. 167. Mattila MJ, Nurminen M-L, Vainio P, et al. Zolpidem 10 mg given at daytime is not antagonized by 300 mg caffeine in man. Eur J Clin Pharmacol 1998 Jul; 54: 421-5
168. 168. Villikka K, Kivistö KT, Luurila H, et al. Rifampin reduces plasma concentrations and effects of zolpidem. Clin Pharmacol Ther 1997 Dec; 62: 629-34
169. 169. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin Pharmacol Ther 1998 Dec; 64: 661-71
170. 170. Luurila H, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. Eur J Clin Pharmacol 1998 Apr; 54: 163-6
171. 171. Piergies AA, Sweet J, Johnson M, et al. The effect of co-administration of zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 1996 Apr; 34: 178-83
172. 172. Allard S, Sainati S, Roth-Schechter B, et al. Minimal interaction between fluoxetine and multiple-dose zolpidem in healthy women. Drug Metab Dispos 1998 Jul; 26: 617-22
173. 173. Allard S, Sainati SM, Roth-Schechter BF. Coadministration of short-term zolpidem with sertraline in healthy women. J Clin Pharmacol 1999 Feb; 39: 184-91
174. 174. Greenblatt DJ, von-Moltke LL, Harmatz JS, et al. Differential impairment of triazolam and zolpidem clearance by short-term low-dose ritonavir. 101st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics: 2000 Mar 15-17: Los Angeles
175. 175. Katz SE. Possible paroxetine-zolpidem interaction [letter]. Am J Psychiatry 1995 Nov; 152: 1689
176. 176. Elko CJ, Burgess JL, Robertson WO. Zolpidem-associated hallucinations and serotonin reuptake inhibition: a possible interaction. J Toxicol Clin Toxicol 1998; 36 (3): 195-203
177. 177. Swedish Adverse Drug RAC. Combination warfarin/zolpidem resulted in increased prothrombin. Bull SADRAC 1998 Oct (67): 5
178. 178. Searle, Zolpidem prescribing information. Skokie, USA, 1993
179. 179. Hoehns JD, Perry PJ. Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia. Clin Pharm 1993 Nov; 12: 814-28
180. 180. Freeman HL. Is there a need for a pure hypnotic? Approaches to the co-diagnosis of insomnia and anxiety. J Drug Dev Clin Pract 1996 Jan; 7: 289-302
181. 181. Costa E Silva JA, Chase M, Sartorius N, et al. Special report from a symposium held by the World Health Organization and the World Federation of Sleep Research Societies: an overview of insomnias and related disorders recognition, epidemiology, and rational management. Sleep 1996; 19 (5): 412-6
182. 182. Chilcott LA, Shapiro CM. The socioeconomic impact of insomnia: an overview. Pharmacoeconomics 1996; 10 Suppl. 1: 1-14
183. 183. Yang C-M, Spielman AJ. The role of behavioural treatment in the management of insomnia. Dis Manage Health Outcomes 1999 Apr; 5: 209-24
184. 184. Walsh JK, Engelhardt CL. The direct economic costs of insomnia in the United States for 1995. Sleep 1999 May; 22 Suppl. 2: S386-393
185. 185. NIH Technology Assessment Panel on Integration of Behavioral and Relaxation Approaches into the Treatment of Chronic Pain and Insomnia. Integration of behavioral and relaxation approaches into the treatment of chronic pain and insomnia. JAMA 1996 Jul 24-31; 276: 313-8
186. 186. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry 1994 Aug; 151 (8): 1172-80
187. 187. Fraser AD. Use and abuse of the benzodiazepines. Ther Drug Monit 1998 Oct; 20: 481-9
188. 188. Lader M. Withdrawal reactions after stopping hypnotics in patients with insomnia. CNS Drugs 1998 Dec; 10: 425-40
189. 189. Kupfer DJ, Reynolds CF III. Management of insomnia. N Engl J Med 1997 Jan 30; 336: 341-6
190. 190. Langer S, Mendelson W, Richardson G. Symptomatic treatment of insomnia. Sleep 1999 Sep 15; 22 Suppl. 3: S437-45
191. 191. Ashton H. Guidelines for the rational use of benzodiazepines: when and what to use. Drugs 1994; 48 (1): 25-40